canertinib dihydrochloride has been researched along with vx-745 in 1 studies
| Studies (canertinib dihydrochloride) | Trials (canertinib dihydrochloride) | Recent Studies (post-2010) (canertinib dihydrochloride) | Studies (vx-745) | Trials (vx-745) | Recent Studies (post-2010) (vx-745) |
|---|---|---|---|---|---|
| 31 | 13 | 6 | 58 | 1 | 35 |
| Protein | Taxonomy | canertinib dihydrochloride (IC50) | vx-745 (IC50) |
|---|---|---|---|
| Mitogen-activated protein kinase 13 | Homo sapiens (human) | 0.0577 | |
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 1 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.0008 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 1 | |
| Adenosine receptor A3 | Homo sapiens (human) | 8.547 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 1 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 8.547 | |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | 0.029 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0008 | |
| Tyrosine-protein kinase ABL2 | Homo sapiens (human) | 1 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 8.547 | |
| Mitogen-activated protein kinase 14 | Mus musculus (house mouse) | 0.0442 | |
| Mitogen-activated protein kinase 12 | Homo sapiens (human) | 0.0577 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 8.098 | |
| Mitogen-activated protein kinase 11 | Homo sapiens (human) | 0.2462 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.4028 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Russu, WA; Shallal, HM | 1 |
1 other study(ies) available for canertinib dihydrochloride and vx-745
| Article | Year |
|---|---|
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |